ClinicalTrials.gg
RecruitingNCT04549688Updated Sep 22, 2023

Active Surveillance Plus (AS+): High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer

An interventional study of high-intensity focused ultrasound, HIFU in Prostate Cancer, sponsored by The Hospital of Vestfold. Recruiting at 1 site in Norway. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by The Hospital of Vestfold · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Prostatic Neoplasms with a site in Norway — 16 open to participants now, 27 under way, 9 of them phase 3. Prostatic Neoplasms · Norway.

Planned enrollment
39th of 66
250 · median 383
Started
2020
with 2 others
No phase
23 of 85
4 open now
Primary completion
2030-09
later than 23 of 26 live
Registered
64th of 85
by date

Among the 85 studies in Prostatic Neoplasms with a site in Norway, this one is the 39th largest by planned enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2020, is one of 23 with no phase, reaches primary completion later than 23 of the 26 other live ones, and was the 64th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

16 of the 85 studies in Prostatic Neoplasms with a site in Norway are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Prostatic Neoplasms with a site in Norway, or all of them as a file.
02

Study summary

PSA (Prostate-specific antigen) testing has significantly increased the number of men diagnosed with prostate cancer (PCa) and especially patients with low and intermediate risk disease. The effect of radical treatment (treatment of the entire prostate gland) in these risk groups is disputable while the risk of adverse effects, with erectile dysfunction and urinary incontinence, is not. Active surveillance (AS) has been developed as an alternative to radical treatment with the aim of avoiding or delaying radical treatment by closely monitoring for signs of tumor progression. Active surveillance is regarded as the treatment of choice for low-risk prostate cancer. Focal therapy may have a crucial role in improving active surveillance protocols for patients with intermediate localized prostate cancer. Focal eradication of the index-tumor may delay or avoid indefinitely radical treatment for this patient group while significantly reducing treatment-related side effects. Improved MRI-diagnostics and MRI/ ultrasound fusion technology have optimized tumor mapping and classification and this in turn has made partial treatment of the prostate a feasible treatment option.

This study is a prospective cohort study. Patients with intermediate (high-risk) localized PCa and a visible index tumor will be treated with high-intensity focused ultrasound (HIFU).

The aim of the study is to show that there is a significant effect of focal treatment on surveillance biopsies and a reduced conversion to radical treatment, without compromising survival outcomes compared to historical controls (retrospective cohort). A cohort from the more than 450 patients included in the local AS-protocol with MRI at Vestfold hospital trust since 2009 will serve as controls.

Read the detailed description

1 Needs description It is unclear if eradication with focal treatment of the index-tumor of patients with intermediate-risk prostate cancer followed by active surveillance can reduce the need for radical, whole-gland treatment of the prostate and thereby treatment side effects. It is important for urologists and patients to know if focal treatment of prostate cancer is both a safe and effective treatment option. If proven so, focal treatment of prostate cancer can be offered as a viable, intermediate treatment option for a large group of patients who currently only have the choice between either surveillance or radical treatment.

Thus, there is an unmet need to document the outcome of focal treatment in selected patients with prostate cancer, both in terms of efficacy and safety

  1. Hypotheses, aims and objectives

2.1 Hypothesis: Focal treatment of biopsy-verified, localized, MRI-visible, intermediate-risk (and high-risk fo elderly patients) prostate cancer is a safe and effective treatment option. Side effects following focal treatment are transient and mild compared to established and well-documented radical treatment options.

2.2 Aims of the study: To investigate if focal treatment of localized prostate cancer followed by MRI-supplemented active surveillance conveys sufficient tumor control to enable patients to continue indefinitely in this follow-up protocol without the need to convert to radical treatment, with none or mild side effects and without compromising oncological outcomes.

2.3 Objectives:

Primary objectives:

  • Eradication of the signal tumor (\<20% positive biopsies in the treated area after one year)
  • Low conversion rates to radical treatment (\<20%)
  • Good long-term oncological results (\<5% metastasis and \<1% prostate cancer deaths at 10 years)
  • Good functional results (\<10% of patients with long-term side effects on erectile function and continence)

Secondary objectives:

  • Evaluation of the ability of MRI to predict biopsy results during follow-up.
  • Health-related quality of life

    1. Methodology

This study is a prospective, single-arm, case-control cohort study with consecutive patients with intermediate-risk, MRI-visible prostate cancer treated focally with HIFU. Participants will be compared to historical controls (patients observed with AS at SiV 2009-2017). The study design follows the international multidisciplinary consensus on trial design for focal therapy in PCa (28, 29). Patients will primarily be recruited from Vestfold-Telemark County but recruitment from other institutions in Norway is encouraged. More formal referral arrangements will be sought with Aleris (Oslo), Telemark Hospital Trust and Vestre Viken Hospital Trust.

3.1 Project arrangements, method selection and analyses From a scientific and methodological point of view a randomized, parallel-group study would have been preferable with patients receiving either AS+ (HIFU) or simple AS follow-up. However, experience from several investigative centers have shown that randomization is difficult to carry out in practice. This is because patients are aware of the HIFU possibility, and, if randomized to standard treatment, often refuse participation and demand HIFU treatment. This problem would likely be exacerbated in this study, where the control group would be offered only follow-up while study arm patients receive tumor-directed treatment with presumed few side-effects. Furthermore, the investigators have learned from own historic controls that AS is "good medicine" for merely half of the patients with intermediate-risk prostate cancer after 5 years. Since it is difficult, based on today's diagnostic tools, to identify patients that will not progress significantly over time, some form of tumor-directed treatment for all patients is sensible. Finally, patients in the historical control group were diagnosed and risk-classified by the same parameters and diagnostic tools that are currently in use. Follow-up of these patients was also very similar to the one outlined for the study patients. The investigators are not aware of any significant change in clinical practice that would suggest that the historical controls at the study institution are not representative of current patients with intermediate risk profile.

Patients who are interested in focal treatment of prostate cancer are aware of the radical treatment alternatives but are skeptical of the side effects. These patients want to know their risk of progression (metastasis and death), the risk of having to undergo radical treatment at a later stage and the short-term and long-term side effects if they choose focal treatment. We believe that this study will provide these answers for a representative Norwegian patient population.

Based on these considerations, the investigators believe that the best and most ethical design is the one proposed here, where all eligible patients receive the same treatment and are then compared to a historical control group.

Study population and Power-estimate Approximately half of active surveillance patients (50%) experience progression of their disease during 5-10 years follow-up (9). This correlates with the outcome of historical AS patients at the study institution.

The investigators estimate that only 20% of the newly diagnosed AS patients receiving HIFU will experience a progression of their disease after 10 years.

In order to detect such a reduction in progression rate, the trial will need to include 194 patients. With 20% expected dropouts, the number of patients needed to include in the HIFU cohort will be 245.

The sample size calculations are based on the ClinCalc program (http://clincalc.com/stats/samplesize.aspx).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • HIFU
  • focal treatment
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 55-80 years
  • >10 years
  • Gleason-score:

    • patients \<75 years: Gleason score \< 8
    • patients 75-80 years: Gleason \<9
  • TNM-stage: clinical/ radiological stage \<T2c (localized), rN0 and rM0
  • PSA \< 15
  • PSA > 15 should be counseled with caution (does not apply to patients >75 years)
  • Risk group: d'Amico intermediary risk group, open for high risk patients age >75 years

Exclusion criteria

Exclusion Criteria:

  • Previous treatment
  • Previous treatment of the primary cancer within the prostate
  • Previous hormone treatment for prostate cancer within 6 months before trial
  • Previous radiation to pelvis
  • Acute urinary tract infection
  • For patients \<75 years: >5% chance of lymph node calculated by the updated prostate cancer staging nomogram (Partin tables) (30)
  • Radiological imaging:
  • PI-RADS score \<3, clinical significant cancer is equivocal
  • Extracapsular extension or seminal vesicle invasion
  • Lymph node or bone metastasis
  • > 2 MRI detected tumors validated by systematic or MRI-guided
  • for MRI
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Focal therapy

    Procedure: high-intensity focused ultrasound, HIFU

Interventions

  • Procedurehigh-intensity focused ultrasound, HIFU

    see above

06

What researchers measure

Primary outcomes

  1. Number of patients without clinically significant prostate cancer

    Absence of clinically significant prostate cancer (Gleason grade ≥7A) on post-treatment systematic and targeted biopsies

    Time frame: 1-10 years

  2. Measurement of functional results

    erectile function, continence, and other therapy-related complications. Questionnaire-based.

    Time frame: 1-10 years

  3. Number of patients who need repeated focal treatment

    recurrence and recurrent treatment

    Time frame: 1-10 years

  4. Number of patients eligible for continuous AS+

    Time frame: 1-10 years

  5. Disease-free survival

    based on repeated MRI and repeat biopsies performed on clinical/ radiological suspicion

    Time frame: 1-10 years

  6. Treatment-free survival

    Time frame: 1-10 years

  7. Overall survival

    Time frame: 1-10 years

  8. Metastasis-free survival

    Time frame: 1-10 years

  9. Number of patients who need radical (surgery or radiation), or palliative treatment (hormone therapy)

    Time frame: 1-10 years

Secondary outcomes

  1. Number of patients where MRI predicted tumor recurrence/ tumor absence

    MRI findings verified by biopsies

    Time frame: 1-10 years

  2. Patient Reported Outcomes Measures

    Survey-based using standard questionaires

    Time frame: 1-10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Sep 2030, 120 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 120 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2020
First posted
Sep 16, 2020
StartActual
Sep 1, 2020
Primary completionEst.
Sep 2030
CompletionEst.
Sep 2030
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04549688
Lead sponsor
The Hospital of Vestfold
Responsible party
Sven Löffeler (Principal Investigator, The Hospital of Vestfold) — Principal investigator
First posted
Sep 16, 2020
Start date
Sep 1, 2020
Primary completion
Sep 2030 (estimated)
Completion
Sep 2030 (estimated)
Last update
Sep 22, 2023

Study contacts

Sven Löffeler, MD, PhD
Contact
sven.loffeler@siv.no
+47-33342000 ext. +4733342000
Sven Löffeler
Contact
sven.loffeler@siv.no
+4733342000 ext. +4733342000
Sven Löffeler
principal investigator · The Hospital of Vestfold

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion